What is DDrare?
DDrare is a database that provides information on drugs in clinical trials, and
drug target genes and pathways, related to the intractable diseases (mostly rare diseases)
designated by the Ministry of Health, Labour and Welfare (MHLW), Japan.
DDrare : Database of Drug Development for Rare Diseases
Data version: Mar2023
|Mar 31, 2023||Data ver. Mar2023. Previous versions are: Mar2022|
|Jan 30, 2023||Med expenses recipients data was updated to FY2021 (338 diseases). FY2020 (333 diseases) data is in ver. Mar2021.|
|Nov 18, 2022||Link to DDrare was added in WHO ICTRP search portal.|
|Oct 25-29, 2022||Poster presentation at ASHG 2022: PB2035. Drug repositioning network in rare and intractable diseases based on drug target gene analyses.|
|Oct 5, 2022||Poster presentation at NBDC TOGO symposium (in Japanese): DDrare Update - Database of Drug Development for Rare Diseases -|
|Mar 31, 2022||Data ver. Mar2022. Updated to the 338 designated intractable diseases in Japan, with new site design and interfaces. Previous versions are: Mar2021, Nov2019|
|Mar 8, 2022||The number of "Medical expenses recipients" was updated to FY2020 data (333 diseases) in Disease.|
|Oct 4, 2021||Links to related pediatric diseases were added in Disease.|
|Sep 28, 2021||DDrare ~ Database of developing drugs, target genes and pathways for rare diseases ~ is added to References.|
|Jun 11, 2021||Our paper "Drug Target Gene-based Analyses of Drug Repositionability in Rare and Intractable Diseases." was published.|
|Mar 30, 2021||Data ver. Mar2021. Database system improvement (sort, filter, etc.) and data updates (new info. of age class of patients, etc.) were conducted.|
|Sep 25, 2020||DDrare - Database of developing drugs, target genes and pathways for rare diseases - is added to References.|
|Sep 25, 2020||Sitemaps for the three entrances (Disease, Drug and Target Gene/Pathway) are equipped.|
|Sep 9, 2020||A few drug names were corrected (12,172 drugs -> 12,170 drugs).|
|Jun 29, 2020||Drugs and target genes shown in Target Gene/Pathway for each disease are now limited to those for the diesase (i.e. Drugs and target genes only for other diseases in a pathway are not shown.). (e.g. Spinal and bulbar muscular atrophy)|
|Jun 22, 2020||English version has opened.|
|Mar 30, 2018||Newly open to public.|
Information of Drug Development extracted from Clinical Trials
Drugs are extracted from clinical trials for the intractable diseases (mostly rare diseases) designated by MHLW, Japan.
Clinical Trials for Rare Diseases in the World’s Four Major Registries
Comprehensive information is available from the four major clinical trial registries of Japan, US, EU and China.
Cross-Reference information for Drug Development
Among Diseases, Drugs, and Target Genes/Pathways, cross-reference is available for target discovery in drug development.
- MHLW Intractable Diseases
Downloaded in Mar 2022
- Japan Intractable Diseases Information Center
Referred in Mar 2022
Release Version 5.1.10 (Jan 2023)
Downloaded in Mar 2023
The information on this website is provided for research purposes only and does not replace the advice or consultation of a doctor. In principle, all rights relating to the information on this website belong to National Institutes of Biomedical Innovation, Health and Nutrition. Please contact us in advance if you would like to use the information on this website. Information on this website is subject to change without notice. In any case, we will not be liable for any damages arising from the use of the information on this website.